Risk Model Validates Finerenone Effect in Heart Failure The Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction (PREDICT-HFpEF) tool effectively stratified cardiovascular risk, with risk being higher in the highest than in the lowest score quintile. Finerenone was consistently effective across risk levels in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), with a large absolute benefit observed in high-risk patients.

Muslim fasting from a medical point of view Dear colleagues!
We offer you an article by Professor Mekhman N. Mamedov about medical aspects of muslim fasting and practical advice for applicants.

Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis Immune checkpoint inhibitors (ICIs) are successful in treating many cancers but may cause immune-related adverse events. ICI-mediated myocarditis has a high fatality rate with severe cardiovascular consequences. Targeted therapies for ICI myocarditis are currently limited. Bill is developing a new therapeutic approach targeting CXCR3 for the treatment of myocarditis with immunotherapy.

Ross Procedure Making a Comeback in Aortic Valve Disease The Ross procedure, which can be used to treat young people with severe aortic valve disease, has seen wide swings in popularity over the years, but now, with consistent data on long-term survival and valve durability, numbers are steadily climbing again.

AHA Advisory Endorses Endovascular Thrombectomy for Large Core Ischemic Stroke Results of six recent trials of endovascular thrombectomy (EVT) for patients with large-core ischemic stroke (LCIS) provide strong evidence for the benefit of this intervention compared with medical management (MM), a new Science Advisory from the American Heart Association (AHA) has concluded.

AI-Enhanced ECG Predicts Hypertension, Related Risks An artificial intelligence–ECG risk estimation model designed to predict incident hypertension (AIRE-HTN) identifies cases and stratifies the risk for adverse outcomes in addition to traditional markers.

CGM Use, GLP-1s, Drinking Water Key of 2025 ADA Standards The American Diabetes Association (ADA)’s Standards of Care — 2025 offer new guidance on broader use of continuous glucose monitoring (CGM), use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) beyond weight loss, management of metabolic dysfunction-associated liver disease (MAFLD), plus a strong endorsement for drinking water and much more.

ADA Advises Against Using Compounded GLP-1 RA Medications In a new statement, the American Diabetes Association (ADA) has advised against the use of compounded glucagon-like peptide 1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA medication classes.

New Trial Result Pushes Past Antiarrhythmic Therapy After MI For ventricular tachycardia after myocardial infarction, outcomes are better with upfront catheter ablation than drug therapy, which is typically used first, the multinational VANISH2 trial shows.

New Pill Successfully Lowers Lp(a) Levels Muvalaplin, a novel oral medication, safely and effectively lowers high levels of lipoprotein(a), or Lp(a), results from the phase 2 KRAKEN trial show.